Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed/Refractory CD19-positive B-ALL”

50 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 50 results

Testing effectiveness (Phase 2)UnknownNCT02892695
What this trial is testing

PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma

Who this might be right for
Acute Lymphocytic LeukemiaChronic Lymphocytic LeukemiaFollicular Lymphoma+3 more
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 10
Early research (Phase 1)UnknownNCT04204161
What this trial is testing

A Clinical Study of CAR-T Cells Treatment for Children With CD19+/CD22+ R/R ALL and Lymphoma

Who this might be right for
Relapsed B-cell Acute Lymphoblastic Leukemia, ChildhoodRefractory B-cell Acute Lymphoblastic Leukemia, ChildhoodRelapsed/Refractory B-cell Lymphoma, Childhood
Shenzhen BinDeBio Ltd. 30
Testing effectiveness (Phase 2)UnknownNCT02851589
What this trial is testing

Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

Who this might be right for
Acute Lymphocytic LeukemiaChronic Lymphocytic LeukemiaFollicular Lymphoma+3 more
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 10
Testing effectiveness (Phase 2)Looking for participantsNCT06213636
What this trial is testing

Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).

Who this might be right for
Acute Lymphoblastic Leukemia, Adult B-CellAcute Lymphoblastic Leukemia, in RelapseNon-Hodgkin Lymphoma, B-cell+4 more
Essen Biotech 75
Early research (Phase 1)UnknownNCT04037566
What this trial is testing

CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma.

Who this might be right for
Leukemia Lymphocytic Acute (ALL) in RelapseLeukemia Lymphocytic Acute (All) RefractoryLymphoma, B-Cell+1 more
Xijing Hospital 40
Early research (Phase 1)Temporarily pausedNCT06447987
What this trial is testing

Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia

Who this might be right for
Recurrent Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic Leukemia
City of Hope Medical Center 24
Very early researchNot Yet RecruitingNCT07330895
What this trial is testing

Clinical Study of LV009 Injection in the Treatment of Recurrent/Refractory CD19 Positive Blood Tumors

Who this might be right for
CD19+ Relapse/Refractory B-ALL
The First Affiliated Hospital with Nanjing Medical University 19
Testing effectiveness (Phase 2)Looking for participantsNCT07244406
What this trial is testing

Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL

Who this might be right for
B-ALL
Hebei Senlang Biotechnology Inc., Ltd. 59
Early research (Phase 1)Looking for participantsNCT06287528
What this trial is testing

19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)

Who this might be right for
Philadelphia-Negative ALLPhiladelphia-Positive ALLRelapsed ALL, Adult+3 more
Memorial Sloan Kettering Cancer Center 18
Early research (Phase 1)UnknownNCT03798509
What this trial is testing

Human CD19 Targeted T Cells Injection Therapy for Relapsed and Refractory CD19-positive Leukemia

Who this might be right for
CD19-positiveAcute Lymphoblastic Leukemia
Hrain Biotechnology Co., Ltd. 18
Early research (Phase 1)Study completedNCT02746952
What this trial is testing

Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia

Who this might be right for
B-cell Acute Lymphoblastic Leukemia
Institut de Recherches Internationales Servier 25
Testing effectiveness (Phase 2)Looking for participantsNCT06533579
What this trial is testing

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

Who this might be right for
B-cell Acute Lymphoblastic LeukemiaLarge B-cell LymphomaChronic Lymphocytic Leukemia+10 more
Vironexis Biotherapeutics Inc. 32
Testing effectiveness (Phase 2)UnknownNCT02819583
What this trial is testing

CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

Who this might be right for
Acute Lymphocytic LeukemiaChronic Lymphocytic LeukemiaFollicular Lymphoma+3 more
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT05460533
What this trial is testing

A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)

Who this might be right for
B-cell Acute Lymphoblastic Leukemia
Memorial Sloan Kettering Cancer Center 30
Early research (Phase 1)Looking for participantsNCT07133997
What this trial is testing

Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia

Who this might be right for
Recurrent B Acute Lymphoblastic LeukemiaRefractory B Acute Lymphoblastic Leukemia
City of Hope Medical Center 26
Testing effectiveness (Phase 2)Looking for participantsNCT07584889
What this trial is testing

Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies

Who this might be right for
B Cell LymphomaAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia
Shenzhen University General Hospital 10
Early research (Phase 1)Active Not RecruitingNCT07166419
What this trial is testing

Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia

Who this might be right for
Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 PositiveRecurrent Acute Lymphoblastic LeukemiaRecurrent Chronic Lymphocytic Leukemia+12 more
Ohio State University Comprehensive Cancer Center
Very early researchUnknownNCT06277011
What this trial is testing

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research

Who this might be right for
Acute Lymphoblastic LeukemiaNon-hodgkin Lymphoma
Anhui Provincial Hospital 18
Early research (Phase 1)Looking for participantsNCT06037018
What this trial is testing

Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies

Who this might be right for
Non-hodgkin LymphomaAcute Lymphoblastic LeukaemiaChronic Lymphocytic Leukemia
CytoCares Inc 44
Testing effectiveness (Phase 2)Study completedNCT01865617
What this trial is testing

Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia

Who this might be right for
CD19-Positive Neoplastic Cells PresentRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Chronic Lymphocytic Leukemia+10 more
Fred Hutchinson Cancer Center 204
Next Page
24